Jay Giri (@jaygirimd) 's Twitter Profile
Jay Giri

@jaygirimd

Interventional cardiologist, CV outcomes & policy researcher, trialist, sports fan, @PennMedicine, @VAPhiladelphia, @PennLDI, tweets reflect only my opinions

ID: 2918175539

linkhttps://www.med.upenn.edu/giri-nathan-lab/personel.html calendar_today12-12-2014 18:33:12

4,4K Tweet

3,3K Takipçi

1,1K Takip Edilen

Jay Giri (@jaygirimd) 's Twitter Profile Photo

Landmark PERSEVERE trial announced European Society of Cardiology 2024 RCT for high risk massive PE: large bore thrombectomy vs standard of care. Mortality 20-30% with standard of care 1 past RCT in this group with only 8 patients. The “Golden Era of PE RCT” continues! sciencedirect.com/science/articl…

Inari Medical (@inarimedical) 's Twitter Profile Photo

Prof Nicolas Meneveau announces the global #PERSEVERE RCT for acute high-risk PE in a full room at #ESCCongress. "PERSEVERE is the first RCT in high-risk PE in 40 years" #FlowTriever #PulmonaryEmbolism #RandomizedTrial #DataMatters #GoldenAge Jay Giri John Moriarty

Prof Nicolas Meneveau announces the global #PERSEVERE RCT for acute high-risk PE in a full room at #ESCCongress.

"PERSEVERE is the first RCT in high-risk PE in 40 years"

#FlowTriever #PulmonaryEmbolism #RandomizedTrial #DataMatters #GoldenAge

<a href="/jaygirimd/">Jay Giri</a> <a href="/JonnyMoriarty/">John Moriarty</a>
RTHahnMD (@hahn_rt) 's Twitter Profile Photo

RHEIA Trial: women w/ severe AS, TAVI using SAPIEN 3/SAPIEN 3 Ultra superior to surgery for primary composite end point of death, stroke, or rehospitalization at one year: superiority driven by lower rate of rehospitalizations. #ESC2024 #ESCCongress2024 European Society of Cardiology

Abdulla A. Damluji, MD, PhD (@drdamluji) 's Twitter Profile Photo

Continuation versus Interruption of Oral Anticoagulation during TAVI: NEJM 🥸 Another TAVR trial: The POPular PAUSE TAVI trial - the names are great #ESCCongress2024 😱 Let's also keep it < 25 points:

Continuation versus Interruption of Oral Anticoagulation during TAVI: <a href="/NEJM/">NEJM</a> 

🥸 Another TAVR trial: The POPular PAUSE TAVI trial - the names are great #ESCCongress2024  

😱 Let's also keep it &lt; 25 points:
Abdulla A. Damluji, MD, PhD (@drdamluji) 's Twitter Profile Photo

🥸 🔟 Major vascular complications occurred more frequently in the continuation group (10.2% vs. 7.7%) 😱Concerns about the safety of uninterrupted anticoagulation during TAVI: bleeding 31.1. vs 21.3%

Davide Capodanno (@dfcapodanno) 's Twitter Profile Photo

The OCEANIC-AF trial, comparing asundexian to apixaban in patients with atrial fibrillation was halted early due to a significantly higher incidence of stroke or systemic embolism in the asundexian group. The findings raise questions about the adequacy of factor XIa inhibition

The OCEANIC-AF trial, comparing asundexian to apixaban in patients with atrial fibrillation was halted early due to a significantly higher incidence of stroke or systemic embolism in the asundexian group. The findings raise questions about the adequacy of factor XIa inhibition
Navin Kapur (@navinkapur4) 's Twitter Profile Photo

For the critical care community these findings may be understood. For non-critical care providers - 24 hrs means limited time to reassess, escalate care, or transfer to another facility. The Golden Day slips by quickly. More to come. #Don’tSleepOnShock Sunil V. Rao Jason N. Katz

Davide Capodanno (@dfcapodanno) 's Twitter Profile Photo

In patients with de novo, non-complex coronary artery disease, irrespective of vessel diameter, a strategy of DCB angioplasty with rescue stenting did not achieve non-inferiority compared with the intended DES implantation in terms of the DoCE at 2 years. This is the first of a

In patients with de novo, non-complex coronary artery disease, irrespective of vessel diameter, a strategy of DCB angioplasty with rescue stenting did not achieve non-inferiority compared with the intended DES implantation in terms of the DoCE at 2 years. This is the first of a
Lina Khan (@linakhanftc) 's Twitter Profile Photo

1. On this Labor Day, a reminder that FTC has issued a rule banning noncompetes. Noncompetes trap millions of workers, blocking them from taking better jobs or starting their own business. Over 25,000 Americans commented on our proposal. Here are some of their stories:

Gregg W. Stone MD (@greggwstone) 's Twitter Profile Photo

Our publ in Lancet: IPD pooled analysis of all 6 RCTs in which 23,256 pts were treated with 1-yr DAPT vs. 2wks-3mos DAPT (median 78d) followed by ticagrelor monoRx. MACE favored short DAPT, and major bleeding and mortality were reduced. Similar results in CCS & ACS, even post-MI.

Our publ in Lancet: IPD pooled analysis of all 6 RCTs in which 23,256 pts were treated with 1-yr DAPT vs. 2wks-3mos DAPT (median 78d) followed by ticagrelor monoRx. MACE favored short DAPT, and major bleeding and mortality were reduced. Similar results in CCS &amp; ACS, even post-MI.
Konstadinos Plestis (@aorticsurgeonmd) 's Twitter Profile Photo

All, I would like to invite you to attend the upcoming 4th Annual Philadelphia Cardiovascular Congress on Thursday - Friday, October 24-25, 2024 at the Bellevue Hotel located in Philadelphia, PA. Register here: lnkd.in/eHYS2yw2 Michael Savage David L. Fischman Jefferson Health

Inari Medical (@inarimedical) 's Twitter Profile Photo

Introducing the #PERSEVERE RCT, continuing our commitment to generating high-quality clinical evidence. ✔ 200 patients randomized 1:1 to #FlowTriever or standard of care ✔ High-risk PE patients ✔ Designed by internationally recognized leaders in PE Thank you to our clinical

Introducing the #PERSEVERE RCT, continuing our commitment to generating high-quality clinical evidence.

✔ 200 patients randomized 1:1 to #FlowTriever or standard of care
✔ High-risk PE patients 
✔ Designed by internationally recognized leaders in PE

Thank you to our clinical
Anil Makam (@anilmakam) 's Twitter Profile Photo

This is a TOTAL mess Physicians face an average of 57 unique quality measures across 8 value-based contracts Many, if not most of these measures are worthless Administrative waste Burnout inducers Costly Takes away from real quality improvement